Transplantation of organs between genetically distinct individuals in the absence of immunosuppression evokes powerful immunological responses to the donor tissue and irrevocably triggers rejection. B cell responses elicited by donor antigens are one of the most vexing barriers to the success of organ transplantation. While donor-specific antibodies' presence and concentration not only correlates with risk but also mediates rejection, just the presence of those antibodies in the recipient’s blood after kidney transplantation does not guarantee rejection. Antibodies and B cell responses can also protect immunological targets, modify the susceptibility of grafts to cellular and humoral immunity, regulate some types of immune responses, as well as contribute to the genesis of tolerance and induce accommodation.
The goal of this research topic is to provide fundamental insights on the functions of antibodies and B cell responses in the context of organ transplantation and how they might impact the diagnosis of rejection, design, and use of new therapeutics and management of organ recipients. It will also provide an overview of how B cell responses determine the outcome of organ transplants and can help predict the risk of profile and outcome after organ transplantation.
We encourage submissions of clinical, translational, and basic research papers. We welcome Original Research as well as Review, Mini-Review and Opinion Articles focusing on, but not strictly limited to, the following topics:
• Analysis of B cell responses to predict the risk of rejection and sensitization after transplantation
• Properties and functions of antibodies elicited in response to transplantation
• Biomarkers, transcriptomic or proteomic profiles that correlate with antibody-mediated rejection or stable graft function
• Discovery and development of new drug targets for the treatment or prevention of antibody-mediated rejection
• New technologies for the early/less invasive diagnosis and treatment of antibody-mediated rejection.
Topic Editor Sophie Brouard is the founder of Osé-Immunotherapeuthics and Biomadvanced. The other Topic Editors declare no competing interests with regard to the Research Topic subject.
Transplantation of organs between genetically distinct individuals in the absence of immunosuppression evokes powerful immunological responses to the donor tissue and irrevocably triggers rejection. B cell responses elicited by donor antigens are one of the most vexing barriers to the success of organ transplantation. While donor-specific antibodies' presence and concentration not only correlates with risk but also mediates rejection, just the presence of those antibodies in the recipient’s blood after kidney transplantation does not guarantee rejection. Antibodies and B cell responses can also protect immunological targets, modify the susceptibility of grafts to cellular and humoral immunity, regulate some types of immune responses, as well as contribute to the genesis of tolerance and induce accommodation.
The goal of this research topic is to provide fundamental insights on the functions of antibodies and B cell responses in the context of organ transplantation and how they might impact the diagnosis of rejection, design, and use of new therapeutics and management of organ recipients. It will also provide an overview of how B cell responses determine the outcome of organ transplants and can help predict the risk of profile and outcome after organ transplantation.
We encourage submissions of clinical, translational, and basic research papers. We welcome Original Research as well as Review, Mini-Review and Opinion Articles focusing on, but not strictly limited to, the following topics:
• Analysis of B cell responses to predict the risk of rejection and sensitization after transplantation
• Properties and functions of antibodies elicited in response to transplantation
• Biomarkers, transcriptomic or proteomic profiles that correlate with antibody-mediated rejection or stable graft function
• Discovery and development of new drug targets for the treatment or prevention of antibody-mediated rejection
• New technologies for the early/less invasive diagnosis and treatment of antibody-mediated rejection.
Topic Editor Sophie Brouard is the founder of Osé-Immunotherapeuthics and Biomadvanced. The other Topic Editors declare no competing interests with regard to the Research Topic subject.